A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors.

Trial Profile

A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2014

At a glance

  • Drugs Cetuximab (Primary) ; Selumetinib (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Nov 2012 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 06 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top